Algorae Pharmaceuticals Limited
LVCLF
$0.0063
$0.000916.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 55.01% | 53.97% | 20.67% | 22.61% | -10.06% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -110.82% | -111.04% | 356.21% | 350.11% | 184.98% |
| Change in Net Operating Assets | -- | -- | -313.25% | -307.65% | -- |
| Cash from Operations | 30.54% | 28.92% | 39.10% | 40.61% | 13.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.47% | 120.94% | 4,370.37% | 4,210.71% | -197.40% |
| Cash from Investing | 120.47% | 120.94% | 4,370.37% | 4,210.71% | -197.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -97.60% | -97.60% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 83.55% | 83.55% | -- |
| Cash from Financing | -- | -- | -99.87% | -99.87% | -- |
| Foreign Exchange rate Adjustments | -50.00% | -50.00% | -116.67% | -116.13% | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 65.79% | 65.00% | -81.81% | -82.28% | -815.13% |